Disclosures for "Proteomic Profiling of Angelman Syndrome for Disease-associated Biomarker Discovery"
-
Dr. Hawtin has received personal compensation for serving as an employee of Ultragenyx. Dr. Hawtin has stock in Ultragenyx Pharmaceutical.
-
Mr. Couthouis has received personal compensation for serving as an employee of Ultragenyx.
-
Mr. Khan has received personal compensation for serving as an employee of Ultragenyx. Mr. Khan has stock in Ultragenyx.
-
Dr. Wang has received personal compensation for serving as an employee of ultragenyx.
-
Ms. Panagoulias has received personal compensation for serving as an employee of Mahzi Therapeutics. Ms. Panagoulias has received personal compensation for serving as an employee of AS2 Bio. Ms. Panagoulias has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neurvati Neurosciences. Ms. Panagoulias has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athira Pharma. Ms. Panagoulias has received research support from NIH.
-
Mr. Gold has received personal compensation for serving as an employee of SomaLogic. Mr. Gold has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for 180 LifeSciences. Mr. Gold has stock in SomaLogic. An immediate family member of Mr. Gold has stock in SomaLogic. An immediate family member of Mr. Gold has stock in SomaLogic. An immediate family member of Mr. Gold has stock in SomaLogic. An immediate family member of Mr. Gold has stock in SomaLogic. An immediate family member of Mr. Gold has stock in SomaLogic. Mr. Gold has received intellectual property interests from a discovery or technology relating to health care.
-
Mr. Daugherty has received personal compensation for serving as an employee of Ultragenyx. Mr. Daugherty has stock in Ultragenyx.
-
Mr. Kunecki has nothing to disclose.
-
The institution of Dr. Berry-Kravis has received research support from NIH. The institution of Dr. Berry-Kravis has received research support from Ionis. The institution of Dr. Berry-Kravis has received research support from Zynerba. The institution of Dr. Berry-Kravis has received research support from Roche. The institution of Dr. Berry-Kravis has received research support from CDC. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation. The institution of Dr. Berry-Kravis has received research support from GeneTx. The institution of Dr. Berry-Kravis has received research support from Angelman Syndrome Foundation. The institution of Dr. Berry-Kravis has received research support from Acadia. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Anavex. The institution of Dr. Berry-Kravis has received research support from Rett Syndrome Research Trust. The institution of Dr. Berry-Kravis has received research support from Ultragenyx. The institution of Dr. Berry-Kravis has received research support from Mallinckrodt. The institution of Dr. Berry-Kravis has received research support from Together Strong Foundation. The institution of Dr. Berry-Kravis has received research support from Orphazyme. The institution of Dr. Berry-Kravis has received research support from Taysha. The institution of Dr. Berry-Kravis has received research support from Erydel. The institution of Dr. Berry-Kravis has received research support from Tetra. The institution of Dr. Berry-Kravis has received research support from Neuren. The institution of Dr. Berry-Kravis has received research support from FRAXA Research Foundation.
-
Dr. Berent has received personal compensation for serving as an employee of Ultragenyx . Dr. Berent has received intellectual property interests from a discovery or technology relating to health care. Dr. Berent has received intellectual property interests from a discovery or technology relating to health care.